Abstract
Injection of DMS subcutaneously, or intravenously, inhibited the PCA response in vivo. [...]inhibition of SPHK in BMMC, by either DMS or specific SPHK 1-siRNA, decreases several effector function, normally triggered during FcεRI aggregation, such as degranulation, the release of proinflammatory cytokines (IL-6, IL-3 and TNF α), as well as the de novo synthesis of the arachidonic acid metabolites such as leukotrienes, and prostaglandins.